Regen BioPharma Inc. (RGBP) Stock Suddenly Gains Momentum: Now What?

Regen BioPharma Inc. (OTCMKTS:RGBP) has been making powerful moves in the charts, and it jumped 51%without any news. The stock is about to break out of trading range and push to its $0.081 April highs, which came following an agreement between KLS, its subsidiary and Oncology Pharma Inc. Following the agreement, Regen gave the Licenses exclusive rights and license to develop and markets specific IP for pancreatic cancer patients’ treatment for 15 years.

This License IP comprises antigen-specific cancer vaccines whereby altered mRNA is given to patients to create epitopes that can trigger an immune reaction, augmenting the possibility of successful immunity induction. Currently, Regen is preparing to update filings and readying outstanding 10K and 10Q reports to upgrade to pink sheet current.

The company also announced that the USPTO would grant patent protection to KCL for an invention pertaining to cancer antigens immunity stimulation by augmenting NR2F6 inhibition to boost T-cell activation. With these developments, RGBP is a stock to watch in the coming months.

Market Reaction:

On Friday, RGBP stock soared 50.6% at $0.0226 with more than 266.98 million shares, compared to its average volume of 206.87 million shares. The stock had moved within a range of $0.0140 – 0.0238 after opening the trade at $0.0145. Over the past 52-week, the stock has been trading within a range of $0.0001 – 0.0819.

Related Posts

About The Author